首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1528865

學名藥市場規模 - 按藥物類型（化療、標靶治療、免疫治療、荷爾蒙治療）、適應症（前列腺、肺、乳癌）、給藥途徑（口服、注射）、配銷通路和全球預測，2024年至2032年

Generic Oncology Drugs Market Size - By Drug Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), Indication (Prostate, Lung, Breast), Route of Administration (Oral, Injectable), Distribution Channel & Global Forecast, 2024 - 2032

出版日期: 2024年05月02日 | 出版商:

Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於癌症盛行率上升、對具有成本效益的治療方案的需求不斷增加以及主要品牌腫瘤藥物專利的到期，預計 2024 年至 2032 年學名藥市場規模將以 5.8% 的複合年成長率擴大。美國國家癌症研究所的資料顯示，2024年，美國將診斷出約2,001,140例新癌症病例。

藥品生產和法規核准的重大進步正在加速高品質學名藥的供應。新興經濟體醫療基礎設施的擴張正在支持對負擔得起的癌症治療的高需求。醫療保健提供者和患者對學名藥的認知和接受程度不斷提高，正在推動該產品的普及。

整個市場分為藥物類型、適應症、給藥途徑、配銷通路和地區。

根據藥物類型，由於癌症盛行率增加、免疫治療研究的進步以及對具有成本效益的治療的高需求，免疫治療藥物領域的行業價值預計在2024 年至2032 年間將以強勁的複合年成長率成長。與傳統療法相比，療效的提高和副作用的減少將增強免疫療法的吸引力。關鍵免疫療法藥物專利的到期、政府對學名藥的支持政策以及人們對免疫治療益處的認知不斷增強也正在擴大該細分市場的成長。

就適應症而言，到2032 年，肺癌領域的學名藥腫瘤藥物市場將獲得巨大的吸引力。的進步。關鍵肺癌藥物的專利到期將提高學名藥的可用性。新興市場醫療保健服務的改善以及早期診斷和治療意識的增強進一步推動了該細分市場的成長。

從區域來看，由於癌症的高盛行率、對負擔得起的治療的需求不斷成長以及主要腫瘤藥物的專利到期，歐洲學名藥市場預計從 2024 年到 2032 年將大幅成長。政府對學名藥生產的大力支持和有利的報銷政策的存在正在加速藥物的部署。醫療保健支出的增加、醫療保健服務取得的改善以及對非專利腫瘤藥物的認知不斷增強，正在推動區域市場的擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 癌症盛行率增加
  - 專利到期
  - 政府對學名藥的支持不斷增加
  - 個人化治療的需求不斷成長
- 產業陷阱與挑戰
  - 保持一致的品質標準
成長潛力分析
管道分析
監管環境
報銷場景
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

主要趨勢
化療藥物
標靶治療藥物
免疫治療藥物
荷爾蒙治療藥物
其他藥物種類

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
攝護腺癌
肺癌
乳癌
大腸直腸癌
白血病
其他適應症

第 7 章：市場估計與預測：按管理途徑，22021 - 2032

主要趨勢
口服
專題
可注射

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：按地區，202021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Apotex Inc.
AstraZeneca
Biocon Ltd.
Gland Pharma Limited
Incyte Corporation
Lupin Pharmaceuticals, Inc.
Mylan N.V.
Natco Pharma Ltd.
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Synthon Pharmaceuticals, Inc.
Teva Pharmaceuticals
Zydus Lifesciences Limited

簡介目錄

Product Code: 4425

Generic Oncology Drugs Market size is projected to expand at 5.8% CAGR from 2024 to 2032, led by the rising prevalence of cancer, increasing demand for cost-effective treatment options, and the expiration of patents for key branded oncology drugs. According to data from the National Cancer Institute, in 2024, approximately 2,001,140 new cases of cancer will be diagnosed in the U.S. The launch of government initiatives and support for generic drug production is also accelerating the product appeal.

Significant advancements in pharmaceutical manufacturing and regulatory approvals are accelerating the availability of high-quality generic oncology drugs. The expansion of healthcare infrastructure in emerging economies is supporting the high demand for affordable cancer treatments. The growing awareness and acceptance of generics among healthcare providers and patients is driving the product uptake.

The overall market is segregated into drug type, indication, route of administration, distribution channel, and region.

Based on drug type, the industry value from the immunotherapy drugs segment is estimated to rise at a robust CAGR between 2024 and 2032, due to increasing cancer prevalence, advancements in immunotherapy research, and high demand for cost-effective treatments. The improving efficacy and fewer side effects compared to traditional therapies will boost the appeal of immunotherapies. The expiration of patents of key immunotherapy drugs, supportive government policies for generics, and growing awareness of immunotherapy benefits are also expanding the segment growth.

With regards to indication, the generic oncology drugs market from the lung cancer segment will gain significant traction by 2032. This is owing to the high prevalence of lung cancer, increasing demand for affordable treatment options, and advancements in generic drug formulations. The expiring patents of key lung cancer drugs will boost generic availability. The improving healthcare access in emerging markets, and the growing awareness of early diagnosis and treatment are further boosting the segment growth.

Regionally, the Europe generic oncology drugs market is estimated to grow at a substantial rate from 2024 to 2032, led by the high prevalence of cancer, rising demand for affordable treatments, and expiration of patents of major oncology drugs. The strong government support for generic drug production and presence of favorable reimbursement policies are accelerating drug deployment. The increasing healthcare expenditure, improving access to healthcare services, and the growing awareness of generic oncology drugs are fueling the regional market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing cancer prevalence
  - 3.2.1.2 Patent expirations
  - 3.2.1.3 Growing government support towards generics
  - 3.2.1.4 Rising demand for personalized treatment
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Maintaining consistent quality standards
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemotherapy drugs
5.3 Targeted therapy drugs
5.4 Immunotherapy drugs
5.5 Hormonal therapy drugs
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Prostate cancer
6.3 Lung cancer
6.4 Breast cancer
6.5 Colorectal cancer
6.6 Leukemia
6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 22021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Topical
7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 202021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 The Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa